Introducing the IDOV™ platform: utilizing oncolytic viruses to target & kill tumor cells with high specificity and efficacy.
Technology
We have developed a “one-shot” cure for deadly cancers.
“The IDOV™ platform builds on past success with two prior generations of viruses that have been injected into hundreds of people worldwide.”
Dr. Nanhai George ChenChief Executive Officer, ViroMissile
How It Works
A single intravenous dose with low “concentration” of viruses is enough to infect and kill cancer cells in tumors and the blood.
Effective at lower dosage because IDOV™ viruses are resistant to inactivation by complement proteins.
Cells infected by IDOV™ viruses are not detected by NK & T-cells, allowing viruses to leak out & infect neighboring cancer cells.
IDOV™ demonstrated broad anti-tumor activity against all types of solid tumors tested.
Even at a low MOI of 0.1, IDOV™ was effective against all 15 human cancer cell lines from nine types of cancer grown as tumor spheroids, with survival rates below 20% after only 4 days.
NOTE: Tumor 3-D cultures are considered to be a more rigorous and representative model than 2-D cultures, similar to avascular tumor nodules, micrometastases, or intervascular regions of large solid tumors.
